

HIF- α Effects on c-Myc Distinguish Two Subtypes of Sporadic *VHL*-Deficient Clear Cell Renal Carcinoma

John D. Gordan,^{1,2} Priti Lal,³ Vijay R. Dondeti,^{1,2} Richard Letrero,^{2,4} Krishna N. Parekh,^{1,2,5} C. Elisa Oquendo,^{2,4} Roger A. Greenberg,^{1,2} Keith T. Flaherty,^{2,4} W. Kimryn Rathmell,⁶ Brian Keith,¹ M. Celeste Simon,^{1,2,5,*} and Katherine L. Nathanson^{2,4}

¹Abramson Family Cancer Research Institute

²Abramson Cancer Center

³Department of Pathology

⁴Department of Medicine

⁵Howard Hughes Medical Institute

University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA

⁶Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

*Correspondence: celeste2@mail.med.upenn.edu

DOI 10.1016/j.ccr.2008.10.016

SUMMARY

von Hippel-Lindau (*VHL*) tumor suppressor loss results in hypoxia-inducible factor alpha (HIF- α) stabilization and occurs in 70% of sporadic clear cell renal carcinomas (ccRCCs). To determine whether opposing influences of HIF-1 α and HIF-2 α on c-Myc activity regulate human ccRCC progression, we analyzed *VHL* genotype and HIF- α expression in 160 primary tumors, which segregated into three groups with distinct molecular characteristics. Interestingly, ccRCCs with intact *VHL*, as well as pVHL-deficient HIF-1 α /HIF-2 α -expressing ccRCCs, exhibited enhanced Akt/mTOR and ERK/MAPK signaling. In contrast, pVHL-deficient ccRCCs expressing only HIF-2 α displayed elevated c-Myc activity, resulting in enhanced proliferation and resistance to replication stress. These reproducible distinctions in ccRCC behavior delineate HIF- α effects on c-Myc in vivo and suggest molecular criteria for selecting targeted therapies.

INTRODUCTION

Mutation or silencing of the von Hippel-Lindau (*VHL*) tumor suppressor gene occurs in a majority of inherited and sporadic clear cell renal carcinomas (ccRCCs) (Banks et al., 2006; Kim and Kaelin, 2004; Kondo et al., 2002b; Lonser et al., 2003). *VHL* encodes pVHL, a critical regulator of the hypoxia-inducible factor (HIF) transcriptional activators (Kim and Kaelin, 2004). HIFs are heterodimeric basic helix-loop-helix/PAS proteins consisting of an α subunit (HIF-1 α or HIF-2 α) and a β subunit (HIF-1 β or ARNT [aryl hydrocarbon receptor nuclear translocator]). HIFs mediate cellular adaptation to low O₂ by activating the transcrip-

tion of target genes involved in metabolism, angiogenesis, and extracellular matrix (ECM) remodeling (Gordan and Simon, 2007; Pugh and Ratcliffe, 2003). pVHL is part of the recognition component of a ubiquitin ligase complex that targets HIF- α subunits for normoxic degradation, a process that is inhibited under hypoxic conditions (typically <5% O₂) by several mechanisms. Although pVHL has additional molecular functions affecting fibronectin assembly (Kim and Kaelin, 2004), microtubule stability (Hergovich et al., 2003), and atypical protein kinase C activity (Lee et al., 2005), results from ccRCC xenograft experiments indicate that HIF- α regulation is critical for *VHL* tumor suppressor function.

SIGNIFICANCE

Constitutive hypoxia-inducible factor (HIF) activity is clearly associated with clear cell renal carcinoma (ccRCC) tumorigenesis; however, the influence of individual HIF- α subunits on cell growth mechanisms in vivo is unknown. Few dominant oncogenic pathways have been identified within ccRCC, making it difficult to select optimal targeted therapies for patients or to predict disease outcome except by grade and stage. Cell culture experiments indicate that HIF-1 α inhibits the c-Myc oncoprotein, whereas HIF-2 α potentiates c-Myc transcriptional activity and cellular proliferation. The findings reported here indicate that HIF-1 α and HIF-2 α promote distinct oncogene activation in human ccRCCs and reveal a critical role for HIF-2 α and c-Myc in promoting genomic integrity. These results suggest that evaluating pVHL status and HIF- α expression may aid targeted therapy selection for human ccRCCs.

HIF-1 α and HIF-2 α have overlapping effects on aspects of angiogenesis and ECM remodeling; however, they also exhibit distinct effects on cell metabolism and proliferation (Gordan et al., 2007b). For example, HIF-1 α is uniquely able to stimulate glycolytic enzyme expression (Hu et al., 2003; Wang et al., 2005) while blocking anabolic biosynthesis by limiting mitochondrial pyruvate consumption (Kim et al., 2006; Lum et al., 2007; Papan-dreou et al., 2006). HIF-1 α also opposes cell-cycle progression in vitro by posttranslationally inhibiting the c-Myc oncoprotein (Koshiji et al., 2004). In direct contrast, HIF-2 α does not regulate glycolytic gene expression (Hu et al., 2003) but uniquely stimulates expression of the stem cell factor Oct-4 (Covello et al., 2006) and promotes cell-cycle progression by enhancing c-Myc-mediated activation of cyclin D2 and E2F1 and repression of p21 and p27 (Gordan et al., 2007a). Intriguingly, independent reports have demonstrated that the HIF-2 α subunit is primarily responsible for the growth of pVHL-deficient human ccRCC xenografts (Kondo et al., 2002a, 2003; Maranchie et al., 2002). Moreover, in VHL disease, the cancer-susceptibility syndrome associated with germline *VHL* mutation, HIF-1 α expression gradually decreases whereas HIF-2 α expression increases as ccRCCs develop (Mandriota et al., 2002; Raval et al., 2005). The differential effects of HIF-1 α and HIF-2 α on c-Myc provide an appealing mechanistic explanation for the activity of HIF-2 α in VHL disease-associated ccRCC (Mandriota et al., 2002; Raval et al., 2005). However, no studies have directly assessed the differential effects of HIF-1 α and HIF-2 α on c-Myc or other oncogenic pathways in human ccRCC.

In addition to driving cellular proliferation, oncogenes can also contribute to genomic instability by disrupting cell-cycle controls and cellular metabolism (Halazonetis et al., 2008). Cell-cycle checkpoint inactivation allows DNA replication in aneuploid cells and may favor oncogenic genomic amplifications by repetitively triggering replication origins during a single S phase (Hook et al., 2007). Furthermore, many oncogenes alter cellular metabolism, leading to the production of reactive oxygen species that directly modify DNA (Lee et al., 1999). Both processes result in disrupted chromosomal structures and replication fork stalling or collapse, triggering a cell-intrinsic DNA damage response (Bartkova et al., 2005; Gorgoulis et al., 2005). In low-stage tumors, this damage causes a G0-like phenotype following incomplete DNA replication (Bartkova et al., 2006; Di Micco et al., 2006), while its impact on more advanced tumors is less clear. High levels of c-Myc overexpression can result in accumulation of significant DNA damage (Ray et al., 2006; Vafa et al., 2002). In contrast, intermediate c-Myc expression levels may actually promote genomic stability, consistent with the observation that DNA damage is reduced when c-Myc is inhibited by HIF-1 α (Huang et al., 2007; Koshiji et al., 2005). Therefore, we also examined the possibility that activation of c-Myc by HIF-2 α might enhance genomic stability in low-stage ccRCCs, thus enhancing tumor cell proliferation by limiting DNA damage checkpoint activation.

In this report, we describe the characterization of more than 160 sporadic human ccRCC tumor samples based on *VHL* genotype and HIF- α expression patterns. Our initial investigations identified three distinct ccRCC groups: (1) tumors with wild-type *VHL* alleles and undetectable HIF- α protein expression (designated “VHL WT”), (2) *VHL*-deficient tumors expressing de-

tectable HIF-1 α and HIF-2 α proteins (designated “H1H2”), and (3) *VHL*-deficient tumors expressing HIF-2 α exclusively (designated “H2”). *VHL* WT, H1H2, and H2 tumors were extensively characterized for differences in cell proliferation, patterns of oncogene activation, and genomic integrity. These analyses were extended to include two independent renal cancer sample sets and HIF-1 α - or HIF-2 α -deficient tumor cell lines. We wished to determine whether human ccRCCs can be subclassified into distinct groups based on *VHL* status and HIF- α expression patterns, which in turn correspond to the activation of distinct oncogenic signaling and DNA repair pathways. The overall objective of these studies is to ultimately provide a strategy to stratify patients for targeted therapies.

RESULTS

Identifying Three Groups of ccRCC

We determined the HIF- α expression patterns and *VHL* status of 57 independent sporadic human ccRCCs obtained from the Collaborative Human Tissue Network (CHTN). HIF immunostaining patterns separated the tumors into three distinct groups: no HIF- α protein detected (“VHL WT,” 12%), both HIF-1 α and HIF-2 α detected (“H1H2,” 61%), or HIF-2 α detected exclusively (“H2,” 27%). Classification was based on HIF- α expression solely in tumor cells. Interestingly, none of the sporadic tumors we evaluated expressed only HIF-1 α , strongly suggesting that HIF-2 α is critical for development of pVHL-deficient human ccRCCs. HIF- α protein staining in H1H2 and H2 specimens was predominantly nuclear and appeared in >75% of tumor cells, whereas *VHL* WT tumors exhibited HIF- α staining in <5% of nuclei (Figure 1A). *VHL* sequencing, copy number, and methylation analysis confirmed that all HIF- α -negative tumors (7 of 7) had wild-type *VHL* alleles, whereas all but one of the HIF- α -positive tumors (49 of 50) harbored biallelic *VHL* inactivation by mutation, deletion, or methylation (Figure 1B; see also Table S1 available online). Most tumors displayed single-allele point or frameshift *VHL* mutations, accompanied by deletion of the remaining allele. The spectrum and relative frequencies of *VHL* mutations were consistent with published analyses of sporadic ccRCC (Banks et al., 2006; Kondo et al., 2002b). Similar to previous observations (Banks et al., 2006; Kondo et al., 2002b), we found two tumors with one deleted and one intact *VHL* allele; of these, one tumor had no HIF- α staining and was classified as *VHL* WT, whereas the other exhibited faint but distinct HIF-2 α staining and was excluded from further analysis.

Multiple controls were performed to substantiate the immunohistochemistry (IHC) and genotyping. As measured by qRT-PCR, *VHL* mRNA levels were reduced to <50% and <20% of normal renal epithelium in *VHL* mutant tumors and *VHL*-methylated tumors, respectively (data not shown). HIF- α protein was measured by western blot assays, and protein levels in the three subgroups were consistent with IHC results. Immunoblots showed low levels of HIF-1 α expression in H2 tumors (<10% of the level in H1H2 tumors), which likely reflects HIF-1 α protein in endothelial cells (Figure S1). By comparing tumor protein extracts to known quantities of epitope-tagged HIF- α protein, we determined that HIF-1 α and HIF-2 α were expressed at essentially equivalent levels in H1H2 tumors (Figure S1 and data not shown). There was no clear difference in *HIF-1 α* mRNA levels between




Figure 1. Categorization of Clear Cell Renal Carcinomas by HIF- α Expression and VHL Status

(A) Representative HIF-1 α and HIF-2 α staining of fresh-frozen tumors categorized as VHL WT, H1H2, or H2. Scale bar = 1 μ m.

(B) Summary of VHL disruption in H1H2 and H2 tumors. Mutations are separated into those occurring in the first two exons or the last.

(C) Summary of clinical parameters for each tumor group. In addition to summarized patient characteristics, histological grade by Fuhrman score and clinical stage by the American Joint Committee on Cancer Tumor Node Metastasis (TNM) system are shown. Tumors scored as T1 or T2 (confined to the kidney) were considered low stage, while T3, T4, and M1 (invasive or metastatic tumors) were considered advanced.

H1H2 and H2 tumors, although slightly increased HIF-2 α mRNA levels were noted in H2 tumors (data not shown). The apparent discrepancy between HIF-1 α mRNA and protein expression in H2 tumors can be explained by multiple mechanisms, including mutant pVHL proteins that selectively promote HIF-1 α degradation (Rathmell et al., 2004) and direct effects of HIF-2 α on HIF-1 α mRNA translation (Raval et al., 2005). Finally, available clinical information was segregated by group, and no significant differences were observed between VHL WT, H1H2, and H2 tumors in either grade or stage of disease at surgery, although VHL WT tumors showed a trend toward more frequent metastasis (Figure 1C).

HIF- α Expression Modulates Oncogene Activation

Based on results from cell culture models (Gordan et al., 2007a), we hypothesized that H2 tumors would display evidence of increased c-Myc activity. Indeed, expression of the c-Myc-activated targets *cyclin D2* and *E2F1* was 2- to 3-fold higher in H2 tumors than in H1H2 or VHL WT tumors when measured by qRT-PCR (Figure 2A). Similarly, the c-Myc-repressed targets *p21* and *p27* were decreased in H2 tumors (Figure 2B). To rule out alterations in overall c-Myc expression levels as an explanation for these results, c-myc mRNA and protein abundance were measured, and no consistent difference was found between groups (Figure 2A and data not shown), nor were significant c-myc amplifications detected with qPCR (Table S1). Ki-67 staining was performed to quantify cell proliferation (Figure 2C), and a 55% increase in Ki-67⁺ nuclei was observed in H2 relative to H1H2 tumors (Figure 2D). The clearest difference was between low-stage tumors, which displayed approximately 60% more Ki-67⁺ nuclei in H2 tumors than in VHL WT or H1H2 tumors, although the analysis of high-stage tumors was limited by the smaller number in this sample set (Figure 2D). Overall, these data support our hypothesis that HIF-2 α activation of c-Myc occurs in human tumor specimens and correlates with increased tumor cell proliferation. Although HIF-2 α is expressed in H1H2 tumors, our previous data show that HIF-1 α -mediated c-Myc in-

hibition directly opposes HIF-2 α -mediated c-Myc activation (Gordan et al., 2007a). Consistent with these data, H1H2 tumors displayed levels of c-Myc target gene expression similar to those in VHL WT tumors.

To extend these analyses in an unbiased manner, mRNA expression profiling was performed to identify global transcriptional effects of differential HIF- α expression. VHL WT tumors were included, both as a comparison group and to identify unique markers of ccRCCs lacking HIF- α expression. Five VHL WT, eight H1H2, and eight H2 tumors were analyzed. These tumors were selected to represent a similar range of early and advanced lesions in each group, and for optimal RNA quality. Comparisons were performed between VHL WT and VHL-deficient tumors and between H1H2 and H2 tumors, identifying a large number of differentially expressed genes (Table S2), a subset of which are discussed further here. These comparisons revealed that H2 tumors expressed elevated levels of additional c-Myc-responsive transcripts involved in the G1/S phase cell-cycle transition (Coller et al., 2000; O'Connell et al., 2003), including *Skp2*, *Cdc7*, *CDT2*, and dihydrofolate reductase (*DHFR*) (Figure 2E; Table S2). In contrast, VHL WT and H1H2 tumors expressed lower but relatively similar levels of these targets, as discussed above. IHC for Skp2 (Figures S2A and S2B) and immunoblotting for Skp2 and Cdc7 (Figure S2C) confirmed that changes in mRNA levels were reflected in protein expression. The c-Myc antagonist *Mxi* was upregulated in VHL-deficient tumors (Corn et al., 2005; Zhang et al., 2007), consistent with decreased expression of c-Myc-regulated mitochondrial enzyme gene expression relative to VHL WT tumors (Table S2). However, *Mxi* appeared to have limited impact on other c-Myc targets, as c-Myc-regulated cell-cycle genes were induced in H2 tumors but not VHL WT tumors despite increased *Mxi* expression.

In striking contrast to c-Myc activation in H2 tumors, H1H2 tumors displayed increased mRNA levels of the genes encoding the growth factor signaling molecules Akt2 and RhoC, as well as ribosomal L, S, and P proteins and the rRNA transcriptional regulator




Figure 2. Upregulation of c-Myc Cell-Cycle Targets and Proliferation in H2 Tumors

(A) Expression of *c-myc* and c-Myc-activated targets as measured by qRT-PCR. Data for *cyclin D2* (*CCD2*), *E2F1*, and *c-myc* in *VHL* WT (*n* = 5), H1H2 (*n* = 8), and H2 (*n* = 8) tumors are shown as fold change relative to pooled normal renal epithelium, ± 1 SEM. *c-myc* expression was tested with two independent primer sets, as it showed a trend toward upregulation (false discovery rate [FDR] = 0.2) in *VHL*-deficient versus *VHL* WT tumors by microarray analysis. *c-myc* expression was highly variable within tumor groups and was not found to be significant by qRT-PCR (*p* > 0.25).

(B) Expression of the c-Myc-repressed targets *p21* and *p27*, shown as in (A).

(C) Representative Ki-67 staining in fresh-frozen tumors, with positive nuclei indicated by red arrowheads. Scale bar = 0.5 μ m.

(D) Summary of Ki-67 staining from stages 1 and 2 (*n* = 4 *VHL* WT, *n* = 9 H1H2, *n* = 8 H2), stages 3 and 4 (*n* = 2 *VHL* WT, *n* = 3 H1H2, *n* = 3 H2), or both combined. Data are shown as mean percentage of Ki-67-positive cells, ± 1 SEM.

(E) Expression of the c-Myc-activated targets and G1/S transition mediators *Skp2*, *CDC7*, *CDT2*, and *DHFR*, analyzed as in (A).

p* < 0.05, *p* < 0.01.

upstream binding factor (UBF). Several of these genes were also expressed at higher levels in *VHL* WT tumors relative to H2 samples (Figure 3A). Intriguingly, we also noted increased expression of genes encoding cytoskeletal proteins in *VHL* WT and H1H2 tumors, which may be a result of enhanced growth factor signaling, given the impact of growth factor-responsive proteins such as RhoC on cell motility. These changes in mRNA levels could represent an adaptive mechanism in H1H2 tumors, as *VHL* loss is associated with decreased matrix deposition and loss of cell polarity (Kim and Kaelin, 2004). To assess growth factor signaling more directly, we performed IHC for phosphorylated extracellular regulated kinase (ERK, also referred to as mitogen-activated protein kinase 1, or MAPK1) and ribosomal protein S6, a target of the mTOR substrate p70 S6 kinase (Figure 3B). These proteins are critical signaling molecules whose phosphorylation is induced by multiple growth factor signal transduction pathways. Increased phospho-S6 and phospho-ERK staining was observed in *VHL* WT and H1H2 compared to H2 tumors (*p* < 0.05 for H1H2 versus H2; Figure 3C). In H2 tumors, detectable phospho-S6 immunostaining was not observed in tumor cells but rather was restricted to stromal cells associated with blood vessels (Figure 3B, red arrowheads). These findings define a functional distinction between ccRCC subsets: whereas c-Myc appears to drive proliferation in H2 tumors, *VHL* WT and H1H2 tumors utilize growth factor signaling pathways acting on ERK and S6.

As expected, the expression profiling experiments also revealed increased expression of genes encoding multiple shared HIF-1 α and HIF-2 α targets (vascular endothelial growth factor, adrenomedullin, etc.) in all *VHL*-deficient tumors. Similarly,

H1H2 tumors (but not H2 tumors) expressed elevated levels of HIF-1 α -specific target genes, such as those encoding glycolytic enzymes (Hu et al., 2003) (Table S2). When two-way clustering was performed on the microarray data, tumors largely segregated into the same groups defined prospectively by HIF- α expression (Figure 3D). Gene ontology analysis (Ficenc et al., 2003) also identified classes of differentially expressed genes in addition to those discussed here (Figure 3D). Thus, the key features of each tumor subtype were consistently observed within groups, with activation of c-Myc targets detected exclusively in H2 tumors, in contrast to upregulated growth factor signaling components in *VHL* WT and H1H2 tumors.

HIF-2 α Limits DNA Damage Accumulation

DNA damage from replication stress is commonly observed in hyperproliferative tumor cells and can trigger a signaling pathway including ATR, ATM, phospho-Chk1, phospho-Chk2, and phosphohistone H2AX (γ H2AX) (Bartkova et al., 2005; Gorgoulis et al., 2005), potentially resulting in cell-cycle checkpoint activation. The ability to repair DNA damage through homologous recombination (HR) and nonhomologous end-joining (NHEJ) overcomes these responses and promotes cellular proliferation. In our expression profiling studies, we observed enhanced expression of genes encoding the HR effectors BRCA1, BARD1, and XRCC2, as well as those encoding the spindle assembly checkpoint proteins BUB1 and CENPE, in H2 tumors compared to *VHL* WT and H1H2 tumors (Table S2). We confirmed these findings with qRT-PCR (Figure 4A). Immunofluorescence for γ H2AX and Ki-67 revealed that H2 tumors contained 50% fewer strongly γ H2AX⁺ nuclei than *VHL* WT or H1H2 tumors, with a clear difference in γ H2AX⁺/Ki-67⁺ nuclei (H2 tumors < 20% of *VHL* WT or H1H2) (Figures 4B and 4C). Phospho-Chk2 staining also correlated to γ H2AX staining patterns (Figure 4D). The dramatic




Figure 3. Microarray Analysis Defines Separable Phenotypes in *VHL* WT, H1H2, and H2 Tumors

(A) Genes associated with growth factor signaling and protein translation significantly upregulated in *VHL* WT and H1H2 tumors relative to H2 tumors. Statistical significance was measured by FDR, and fold differences relative to H2 are shown. Gene names shown in bold were confirmed by qRT-PCR in *VHL* WT (n = 5), H1H2 (n = 8), and H2 (n = 8) tumors. Results for genes encoding elF3 and ribosomal protein (rp) L, S, and P subunits are the average of those shown.

(B) Representative immunohistochemistry (IHC) for phospho-S6 and phospho-ERK in fresh-frozen *VHL* WT, H1H2, and H2 tumors. Red arrowheads indicate blood vessels. Scale bar = 5 μ m.

(C) Summary of phospho-S6 and phospho-ERK levels in *VHL* WT, H1H2 and H2 tumors, scored as weak, intermediate, or strong based on intensity of staining. n = 5, 12, and 11, respectively. *p < 0.05.

(D) Two-way complete linkage clustering of significantly altered genes between each subgroup identifies both tumors and genes that show similar patterns of expression. Tumor subtypes are identified by color, with *VHL* WT highlighted in green, H1H2 in blue, and H2 in red. Red indicates higher levels of expression. The gene set involved in cell cycle and DNA damage responses is highlighted, as this group was selected for further study.

decrease in γ H2AX⁺/Ki-67⁺ nuclei in H2 tumors strongly suggests that they accumulate less DNA damage during replication. DNA damage was directly measured by assessing the percentage of the genome that was aberrant (amplified or deleted) in 10 H1H2 and 11 H2 tumors by array-based copy number analysis. Of note, a statistically significant 40% reduction was noted in H2 tumors (Figure 4E).

As our expression data implicated HR effectors in DNA damage responses in H2 tumors, we assessed protein abundance and function by immunofluorescence. When tumor sections were stained for BARD1, expression was detected at homogeneous levels within each section, but differences were noted in the number of foci between tumors (Figure 5A). There was a statistically significant increase in the number of H2 tumors with moderate to high numbers of BARD1 foci (defined as 15–30 and >30 foci per nucleus, respectively) compared to H1H2 tumors. This difference was also significant when H2 tumors were compared to H1H2 and *VHL* WT tumors grouped together (Figure 5B). Whereas BARD1 staining tended to be homogeneous within tumor sections, BRCA1 staining (Figure 5C) was more variable between nuclei for a given tumor. BRCA1 was present in a higher proportion of all nuclei in H2 tumors, including those that were γ H2AX⁺ (Figure 5D), suggesting that HR activity reduces the accumulation of stalled and collapsed replication forks in H2 tumors.

To test the role of HIF- α subunits in HR effector expression directly, we employed a *VHL* mutant ccRCC cell line (RCC4) that expresses both HIF-1 α and HIF-2 α . Vector-transduced control cells were compared to HIF-1 α knockdown (H1KD) cells (“H1KD.1” and “H1KD.2”) or HIF-2 α knockdown (H2KD) cells (“H2KD.1” and “H2KD.2”) (Figure 6A; Figure S3A). Expression of a common HIF-1 α and HIF-2 α target gene (*VEGF*), a HIF-1 α -specific target gene (*PGK*), and a HIF-2 α -specific target gene (*Oct-4*) (Covello et al., 2006; Hu et al., 2003) was assessed to confirm functional HIF- α knockdown in these cells (Figure S3B). H1KD cells retain HIF-2 α activity and displayed enhanced c-Myc activity with elevated *cyclin D2* and *E2F1* expression and decreased *p21* and *p27* expression. In contrast, decreased c-Myc activity was observed in H2KD cells, which retain HIF-1 α expression (Figure 6B). Similarly, HIF-1 α knockdown promoted S phase entry, enhancing proliferation, whereas HIF-2 α knockdown caused accumulation in G1 and limited proliferation (Figures S3C and S3D). Expression of other c-Myc targets, including *Skp2*, *CDC7*, *BARD1*, and *BRCA1*, was found to be stimulated by HIF-1 α knockdown (Figure 6C) and inhibited by HIF-2 α knockdown, consistent with our observations using primary ccRCCs. Although these mRNA changes are modest, they are likely to have additive effects. In the case of *BRCA1*, they also correspond to more dramatic changes in protein expression (Figure 6D). HIF-1 α and HIF-2 α effects on *BRCA1* and *BARD1* mRNA expression were c-Myc dependent based on siRNA knockdown of c-Myc expression (Figure 6E), consistent with previous studies showing that c-Myc stimulates *BRCA1* expression (Bindra et al., 2005;




Figure 4. H2 Tumors Exhibit Decreased Accumulation of γ H2AX and Genomic Aberrancy

(A) Enhanced expression of genes associated with homologous recombination (HR) and the spindle assembly checkpoint in H2 tumors. Data from VHL WT (n = 5), H1H2 (n = 8), and H2 (n = 8) tumors are shown as fold change relative to pooled normal renal epithelium, ± 1 SEM. *p < 0.05, **p < 0.01. (B) Representative γ H2AX/Ki-67 costaining in fresh-frozen VHL WT, H1H2, and H2 tumors. DAPI was used to identify nuclei. Scale bar = 0.2 μ m.

(C) Quantification of γ H2AX staining in all cells and in Ki-67⁺ cells from VHL WT, H1H2, and H2 tumors (n = 6, 12, and 11, respectively), ± 1 SEM. **p < 0.01. Significant differences also were observed for H1H2 and H2 between all nuclei and Ki-67⁺ nuclei (p < 0.05).

(D) Characteristic phospho-Chk2/ γ H2AX costaining in representative VHL WT, H1H2, and H2 tumors. Scale bar = 0.2 μ m.

(E) Measurement of copy number by Illumina SNP arrays in H1H2 and H2 tumors shows that a significantly lower percentage of the genome is aberrant in H2 tumors. *p < 0.04.

Koshiji et al., 2004). Thus, manipulating the stoichiometry of HIF-1 α and HIF-2 α in RCC4 cells can modulate c-Myc activity, resulting in altered expression of HR mediators.

H1KD and H2KD cells were also evaluated for their response to hydroxyurea (HU)-induced replication stress. HU blocks nucleotide synthesis and inhibits DNA replication, resulting in replication fork stalling and ATR-mediated Chk1 phosphorylation. Failure to resolve stalled replication forks leads to their collapse and activation of ATM, Chk2, and p53, which can promote cell-cycle arrest or senescence (Branzei and Foiani, 2007; Wang, 2007). Resolution of stalled forks requires HR, which is known to occur in BRCA1 nuclear foci (Wang, 2007). HU-treated H1KD (HIF-2 α -expressing) cells displayed >50 BRCA1 foci per nucleus, whereas <10 foci were detected in H2KD (HIF-1 α -expressing) cells. We also noted that H1KD cells exhibited less dramatic γ H2AX staining when compared to control or H2KD cells (Figure 6F). In each case, BRCA1 and γ H2AX foci displayed overlapping nuclear distributions (Figure 6F). These data are consistent with the large number of BRCA1 foci observed in H2 tumors and suggest a specific role for HIF-2 α in DNA damage response in ccRCCs.

Functional consequences of differential DNA damage signaling in HIF- α knockdown cells were examined. HU treatment of cells synchronized in S phase induced rapid Chk1 phosphoryla-

tion in all lines, suggesting equivalent activation of the intra-S phase checkpoint (Figure 7A). In contrast, Chk2 phosphorylation and γ H2AX were decreased in H1KD cells compared to control cells, mirroring the differences observed between H2 and H1H2 tumor specimens (Figure 7A, left panel), while the opposite result was observed in H2KD cells (Figure 7A, right panel). Interestingly, H1KD cells returned more rapidly to cell-cycle progression after HU treatment, whereas H2KD cells recovered more slowly (Figure 7B). These data support the notion that HIF-2 α , in contrast to HIF-1 α , promotes more efficient HR-mediated repair and resolution of replication stress, reducing the accu-

mulation of DNA damage and activation of checkpoint responses.

We used an independent experimental approach to evaluate the effect of HIF- α expression on cell-cycle progression under conditions of replication stress. Cells were incubated for 20 hr in 1 μ g/ml aphidicolin, a concentration at which aphidicolin reduces DNA polymerase progression through complex genomic structures and can activate an intra-S phase checkpoint characterized by cells with hyperdiploid DNA content (>2N). In RCC4 cells, HIF-1 α knockdown promoted successful completion of S phase as indicated by a significant decrease in the proportion of >2N cells compared to control lines (Figure 7C), consistent with the hypothesis that these cells respond more effectively to DNA replication stress. In contrast, H2KD cells showed a trend toward failure to complete S phase (p = 0.06). Interestingly, cells completing G1 in the presence of low-dose aphidicolin treatment are capable of firing early origins of replication and incorporating bromodeoxyuridine (BrdU), although DNA synthesis at newly fired origins is severely diminished (Dimitrova and Gilbert, 2000); consequently, these cells appear as BrdU positive with 2N DNA content (2N/BrdU⁺). H1KD and H2KD cells were treated with aphidicolin as described above and then pulsed with BrdU for 20 min to label newly fired origins in cells that had successfully completed G1. H1KD cells showed a significantly higher




Figure 5. H2 Tumors Show Enhanced Signs of HR-Mediated Repair

(A) Representative BARD1 staining with DAPI to indicate nuclei in *VHL* WT, H1H2, and H2 tumors. Scale bar = 0.1 μ m. (B) Quantification of BARD1 nuclear staining in *VHL* WT (n = 4), H1H2 (n = 11), and H2 (n = 12) tumors. Weak staining was scored as 0–15 foci/nucleus, intermediate as 15–30, and strong as >30. (C) Representative BRCA1/ γ H2AX costaining in *VHL* WT, H1H2, and H2 tumors. Scale bar = 0.1 μ m. (D) Quantification of BRCA1 foci in γ H2AX⁺ nuclei from *VHL* WT, H1H2, and H2 tumors, \pm 1 SEM. *p < 0.05, **p < 0.01.

rate of replication initiation compared to controls, reflected as 2N/BrdU⁺ cells, whereas H2KD cells showed significantly lower rates (Figure 7C). In summary, HIF-2 α expression (in the absence of HIF-1 α) was correlated with increased *BRCA1* expression and efficient S phase completion, thereby permitting cell-cycle progression in the face of replication stress while limiting phospho-Chk2 and γ H2AX accumulation. Conversely, HIF-1 α expression was associated with elevated markers of DNA damage and a limited ability to proliferate when challenged with replication stress, in keeping with the model presented in Figure 7D. Importantly, results from these functional in vitro studies using replication stress mimetics are consistent with our observations of DNA stress markers in ccRCC tumors.

Validation of Expression and Signaling Changes in Additional Tumor Samples


Having identified HIF- α -intrinsic effects on cell-cycle and DNA repair pathways in human tumor specimens, we sought to confirm them in two independent sets of patient samples. Microarray analysis was performed on a second group of 12 ccRCCs, collected at the University of North Carolina. All tumors were scored as *VHL* deficient because they showed strong HIF- α staining in >75% of cells, significant upregulation of multiple HIF targets, and decreased *VHL* expression compared to controls. Samples were separated into H1H2 and H2 subgroups (n = 7 and 5, respectively), and differentially expressed genes were analyzed. As described above, tumors clustered by HIF- α expression (Figure S4A), exhibiting gene expression consistent with increased glycolytic metabolism and growth factor signaling in H1H2 tumors and enhanced cell-cycle progression and HR gene expression in H2 tumors. Comparing these results to our primary analysis, we observed a 30%–40% concordance between the data sets (p < 1 \times 10^{−12}), commensurate with published reports comparing arrays performed under similar conditions (Subramanian

et al., 2005). Ki-67 staining (Figure S4B) was also consistent with data from our initial tumor set. Genes exhibiting increased expression in all H2 tumors are listed in Figure S3C and include those encoding cyclin D2, E2F1, Skp2, DHFR, BARD1, and BRCA1.

To confirm the biological phenotypes described above and to analyze a data set with information regarding clinical outcome, IHC was performed on a tissue microarray (TMA) containing triplicate samples from 93 randomly selected ccRCCs from the University of Pennsylvania. TMA slides were immunostained for HIF-1 α and HIF-2 α proteins (Figure 8A), and a similar distribution of the three groups was observed (Figure 8B). Tumors were categorized as *VHL* WT if neither HIF-1 α nor HIF-2 α staining was observed. The tumors in this data set tended to be of lower stage than the initial group, but a similar proportion were metastatic at presentation. Metastatic relapse was observed in H1H2 and H2 tumors over a median 6 years of follow up, with comparable overall rates between groups (Figure 8B). Notably, H2 tumors were significantly larger in volume compared to *VHL* WT or H1H2 tumors (Figure 8B; p < 0.008 and 0.04, respectively). Ki-67, phospho-S6, and γ H2AX staining was performed, and H2 tumors displayed 60% more Ki-67⁺ cells relative to H1H2 and *VHL* WT tumors (Figure 8C), whereas phospho-S6 (Figures 8D and 8E) and γ H2AX (Figures 8F and 8G) staining was significantly higher in both *VHL* WT and H1H2 compared to H2 tumors. These data extended our analysis of HIF- α effects to advanced tumors, which had not previously been possible in the smaller initial tumor collection. These two data sets (105 additional samples) confirm and extend the phenotypic characterization of the initial ccRCC subgroups (Figure 1), as well as the increased expression of specific gene targets in H2 tumors (Table S2) associated with increased cell-cycle progression and HR.

DISCUSSION

Human ccRCCs are typically subdivided into two distinct groups based on *VHL* status. Approximately 70% of sporadic ccRCCs have lost pVHL expression through *VHL* deletion and/or silencing (Banks et al., 2006; Kim and Kaelin, 2004), but additional criteria by which pVHL-deficient tumors can be classified have not been described. Here, we demonstrate that *VHL*-deficient ccRCCs can be distinguished on the basis of differential HIF- α



expression and consequent HIF-dependent effects on c-Myc activity. Specifically, we found that H2 tumors displayed enhanced c-Myc activity, higher rates of proliferation, increased volume, and lower levels of γ H2AX accumulation than H1H2 or *VHL* WT tumors. In contrast, H1H2 and *VHL* WT tumors displayed increased activation of Akt/mTOR and ERK/MAPK1 growth factor signaling pathways and enhanced γ H2AX accumulation. Although *VHL* WT and H1H2 tumors generally share these traits, prior work (Turner et al., 2002) and our expression profiling data strongly suggest that H1H2 tumors are more angiogenic than *VHL* WT tumors. This study presents evidence of differential HIF/c-Myc effects in patient-derived tumor samples and describes a previously unappreciated interplay between HIF-2 α , c-Myc, and genome stability. Together, these data provide a mechanistic basis on which to subdivide ccRCCs for molecularly targeted therapy.

The in vitro and in vivo findings presented here extend HIF-2 α /c-Myc cell-cycle effects to include promotion of efficient transit through S phase by stimulating expression of HR mediators, as well as genes encoding proteins that limit replication stress by enhancing nucleotide pools (DHFR) (Milbrandt et al., 1981) or blocking rereplication (Skp2 and Cdt2) (Nishitani et al., 2006). As HIF-1 α and HIF-2 α have opposite effects on c-Myc, our findings are consistent with previous observations that HIF-1 α inhibits mismatch repair by blocking c-Myc activity (Koshiji et al., 2005). It should be noted, however, that hypoxia directly promotes genomic instability in a HIF-1 α -independent fashion

(Bristow and Hill, 2008). Thus, tumors expressing only HIF-2 α may be able to compensate for hypoxia-induced genomic instability. Intriguingly, our findings suggest that *Mxi* upregulation by HIF-1 α and HIF-2 α (Zhang et al., 2007) exerts a specific effect on mitochondrial metabolism without impacting several other c-Myc-driven processes. These results delineate the in vivo impact of HIF/c-Myc effects in ccRCC and highlight contrasting properties of HIF-1 α and HIF-2 α in c-Myc-regulated DNA damage repair.

The decreased levels of γ H2AX and increased numbers of Ki-67 $^{+}$ nuclei observed in H2 tumors reveal a correlation between enhanced proliferation and decreased levels of DNA damage. Given the concomitant upregulation of the HR effectors *BRCA1* and *BARD1*, these findings implicate enhanced resolution of replication stress as a mechanism by which tumor cells escape the cell-cycle block imposed by DNA damage-activated checkpoints. The fact that HIF-2 α -expressing RCC4 cells, which display enhanced *BRCA1* and *BARD1* expression, recover more rapidly from HU and aphidicolin further supports the hypothesis that enhanced HR contributes to tumor cell proliferation in the context of replication stress. Similarly, a key role for HR in normal cell-cycle progression has been suggested by targeted mutation of murine *Brca1* and *Bard1*, as disruption of either gene dramatically limits proliferation in embryonic cells (McCarthy et al., 2003; Xu et al., 1999). Differing levels of replication stress could underlie the variable activation of DNA damage response machinery observed in different tumor types. For example, whereas




Figure 7. HIF-2 α /c-Myc Effects Correlate with Resistance to Replication Stress

(A) Western blot analysis of Chk1, Chk2, and γ H2AX phosphorylation following 1.5 mM HU treatment of control and HIF- α knockdown cell lines synchronized in S phase by timed release from serum withdrawal and confluency. Total Chk1, Chk2, H2AX, and actin are shown as controls.

(B) Return to DNA replication following 1 hr treatment of S phase-synchronized cells with 1.5 mM HU, measured by BrdU incorporation. Average percentage of BrdU⁺ cells are shown from three experiments, \pm 1 SEM. Statistically significant differences between Ctl1 and H1KD.1, Ctl2 and H2KD.2, and H1KD.1 and H2KD.2 were assessed. * p < 0.05.

(C) BrdU incorporation in cells grown for 20 hr in the presence of 1 μ g/ml aphidicolin. Percentage of cells with >2N DNA content is shown, as is the 2N/BrdU⁺ percentage. Data are from one representative experiment, \pm 1 SD. * p < 0.05, ** p < 0.01.

(D) Simplified model outlining responses to replication stress. Various stress inducers have been shown to activate ATR, leading to Chk1 phosphorylation and DNA repair, with replication fork collapse activating ATM, enhancing γ H2AX accumulation, and promoting cell-cycle exit. These data are consistent with a model wherein HIF-2 α promotes the former pathway (highlighted in red) and HIF-1 α -expressing cells tend to exhibit the latter (highlighted in blue).

tumors of the lung, bladder, and skin appear dependent on stepwise dismantling of DNA damage responses for progression (Bartkova et al., 2005; Gorgoulis et al., 2005), recent studies suggest that stomach, colorectal, and breast adenocarcinomas, as well as testicular germ cell tumors, have minimal DNA damage response activation at all stages (Bartkova et al., 2007; Nuciforo et al., 2007). More efficient progression through S phase has not been previously described as a pathway for enhanced tumor cell proliferation and is likely to be of particular importance in early-stage tumor cells with intact DNA damage checkpoints.

The combination of *VHL* genotype and HIF- α expression allows the stratification of ccRCCs into biologically distinct groups and suggests a framework for subclassifying tumors for targeted therapies. Although several targeted drugs with distinct mechanisms of action are available to treat metastatic ccRCC, there are currently no parameters to select the optimal drug for each patient. Sunitinib and sorafenib each appear to inhibit tumor angiogenesis and tumor cell viability through their effects on VEGF signaling in endothelial cells and, potentially, tumor cells. These agents differ with respect to the potency of their interactions with VEGF and PDGF receptors, most notably with respect to the Raf/MAP kinase pathway, an exclusive target of sorafenib. We suggest that growth factor-driven ccRCCs (*VHL* WT and H1H2) are more likely to respond to these drugs. Similarly, while treatment with erlotinib (targeting the epidermal growth factor receptor) and bevacizumab (inhibiting angiogenesis) confers no benefit as compared to bevacizumab alone in

unselected patients (Motzer and Bukowski, 2006), this combination might exclusively show increased efficacy against the H1H2 subset. Furthermore, whereas the antiangiogenic effects of sorafenib and sunitinib should impact the vasculature in H2 tumors, these tumors are nevertheless likely to progress, as HIF-2 α -dependent c-Myc activation could promote growth in relatively well-oxygenated tumor subdomains. Expression of HIF-2 α alone may therefore mark a subset of RCCs that are uniquely resistant to the current targeted therapeutics. While retrospective and prospective studies are needed to demonstrate a connection between HIF- α expression and therapeutic response, HIF- α analysis enables us to stratify ccRCC patients and thus examine predictors of outcome based on biological differences in clinical trials of targeted therapies.

EXPERIMENTAL PROCEDURES

Patient Material

Frozen material for primary analysis was obtained through the Collaborative Human Tissue Network. OCT-embedded blocks were sectioned until cut planes were >70% tumor. Sections were collected for DNA, RNA, and protein extraction. Material for tissue microarray (TMA) analysis was obtained from archival specimens at the University of Pennsylvania. Both protocols were approved by the University of Pennsylvania Institutional Review Board. Samples were cataloged, clinical information on cases was obtained through chart review, and patient identifiers were removed before analysis. Material for microarray validation was collected at the University of North Carolina from surgeries performed on site. Approval was given by the University of North Carolina Institutional Review Board.




Figure 8. Tissue Microarray Analysis of Biological Parameters and Patient Outcome

(A) Representative HIF-1 α and HIF-2 α staining from paraffin-embedded tissue microarray (TMA) cores. Scale bar = 2 μ m.

(B) Summary of patient information and clinical outcomes across IHC-determined groups. Volume is shown in cm³. * $p < 0.05$.

(C) Summary of Ki-67 staining from low- and high-stage tumors or both combined. Data are shown as mean percentage of Ki-67-positive cells, ± 1 SEM. * $p < 0.05$, ** $p < 0.01$.

(D) Representative phospho-S6 staining. The VHL WT and H1H2 sections shown were scored as intermediate and the H2 section as negative, though endothelial cell phospho-S6 can be noted (red arrowheads). Scale bar = 0.5 μ m.

(E) Summary of phospho-S6 staining in VHL WT, H1H2, and H2 tumors. * $p < 0.05$, ** $p < 0.01$.

(F) Representative γ H2AX shown with DAB and fluorescent staining. Middle row also shows DAPI so that negative nuclei can be discerned, whereas bottom row shows only γ H2AX. Scale bars = 2 μ m (top), 0.5 μ m (middle), and 0.2 μ m (bottom).

(G) Quantification of fluorescent γ H2AX staining in all tumors, ± 1 SEM. * $p < 0.05$, ** $p < 0.01$.

and renal angiomyolipomas and spleen cores were also included as staining controls. Cores were assembled and cut into sections as described previously (Kononen et al., 1998).

Microarrays

Primary expression microarray analysis was performed at the University of Pennsylvania Microarray Core using the Affymetrix U133 Plus 2.0 array,

with analysis using GenePattern (Broad Institute of MIT and Harvard) (Reich et al., 2006). Array-based comparative genomic hybridization was also performed at the University of Pennsylvania Microarray Core using the Illumina 550K-2 v3.1 array and analyzed using Partek Genomics Suite, while the validation set of expression arrays was hybridized at the University of North Carolina Genomics Core using the Agilent 4x44K array format, with a standard reference RNA used in the second channel and analyzed with statistical analysis of microarrays. Analytical methods are described in Supplemental Experimental Procedures.

Statistical Analysis

Significance was typically evaluated by two-tailed Student's *t* test. When *t* tests were performed on data from multiple measurements (e.g., counting four images of one slide), values were averaged by tumor before inclusion in the test. For noncontinuous measurements, Fisher's exact test was used with 2 \times 2 tables, except for phospho-S6 and phospho-ERK staining, where 2 \times 3 and 3 \times 3 chi-square tables were used.

Cell Culture, Drug Treatments, and Synchronization

RCC4 cells were cultured in DMEM with 10% FCS (Gemini), standard additives, and 1 μ g/ml puromycin. Knockdown clones were generated by retroviral transduction using pBABE HIF-1 α shRNA (Lum et al., 2007) and pRETROSUPER HIF-2 α shRNA (Kondo et al., 2003) (generous gift of W.G. Kaelin, Dana-Farber Cancer, Boston). Hydroxyurea (Sigma) was prepared in water and used at 1.5 mM. Aphidicolin was prepared in DMSO and used at 1 μ g/ml. Cells were synchronized in G1 by confluency and serum withdrawal for 24 hr and released by trypsinization and replating. H1KD, control, and H2KD cell lines were released 18, 20, and 22 hr before HU treatment, respectively, ensuring that 50%–60% of cells were in S phase and the remainder in

VHL Sequence and Methylation Analysis

DNA was extracted from tumor samples using an EX-WAX DNA extraction kit (Chemicon). Mutation screening was performed on PCR-amplified exons by direct sequencing with a BigDye Terminator Cycle kit on a 3130xl sequencer (Applied Biosystems). Primers and protocols were used as described previously (Stolle et al., 1998). Methylation studies were performed using a CpG Wiz kit (Chemicon) and/or NotI digestion (Herman et al., 1994).

Immunohistochemistry

For frozen specimens, 10 μ m sections were fixed with 4% paraformaldehyde, permeabilized with PBS/0.5% Triton X-100, and stained following standard protocols detailed further in Supplemental Experimental Procedures. For HIF- α staining, slides were scored as positive if more than 40% of nuclei stained positive. Cytoplasmic staining was not considered. For Ki-67, Skp2, γ H2AX, phospho-Chk2, and BRCA1, 3–4 high-power images were counted for percentage positive and then averaged to give a mean rate per tumor, except for Ki-67 on TMA cores, where the entire core was counted in each case. Only cells with clear tumor cell morphology were scored. For phospho-ERK, phospho-S6, and BARD1, samples were scored as negative/weak, intermediate, or strong. For these and for HIF- α staining, analysis was performed by multiple investigators, including J.D.G., P.L., and K.N.P.

TMA Design and Production

Ninety-four ccRCC samples were selected from tissue archives at University of Pennsylvania, representing ninety-three primary tumors and one metastasis. Hematoxylin and eosin-stained sections were evaluated to confirm the initial diagnosis, and three 0.6 mm tissue cores were selected from different areas of each tumor. Matched normal renal epithelium was included for 2/3 of cases,

G1. All other in vitro methods are described in [Supplemental Experimental Procedures](#).

ACCESSION NUMBERS

The raw data for expression profiling and single-nucleotide polymorphism (SNP)-based copy number data are available through the NCBI Gene Expression Omnibus (GEO) at <http://www.ncbi.nlm.nih.gov/geo/> with the accession numbers GSE11904 and GSE11985 for expression profiling data (University of Pennsylvania and University of North Carolina, respectively) and GSE13282 for SNP-based copy number data.

SUPPLEMENTAL DATA

The Supplemental Data include Supplemental Experimental Procedures, four figures, and two tables and can be found with this article online at [http://www.cancercell.org/supplemental/S1535-6108\(08\)00366-8](http://www.cancercell.org/supplemental/S1535-6108(08)00366-8).

ACKNOWLEDGMENTS

We are grateful to many members of the Abramson Family Cancer Research Institute, J. Tomaszewski and T. Pasha of the University of Pennsylvania Pathology Department, and D. Baldwin and J. Tobias of the Penn Center for Bioinformatics for advice and discussions. This work was supported by NIH Program Project Grant CA104838, the Howard Hughes Medical Institute, and the DiBona Foundation. J.D.G. was supported by a NIH Medical Scientist Training Grant and a NRSA T32 grant for Hemostasis and Thrombosis. W.K.R. was supported by NIH grant R01 CA01121781 and the V Foundation. M.C.S. is an Investigator of the Howard Hughes Medical Institute. Tissue samples were provided by the Cooperative Human Tissue Network, which is funded by the National Cancer Institute. Other investigators may have received samples from these same tissues.

Received: June 14, 2008

Revised: September 30, 2008

Accepted: October 24, 2008

Published: December 8, 2008

REFERENCES

- Banks, R.E., Tirukonda, P., Taylor, C., Hornigold, N., Astuti, D., Cohen, D., Maher, E.R., Stanley, A.J., Harnden, P., Joyce, A., et al. (2006). Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. *Cancer Res.* 66, 2000–2011.
- Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J.M., Lukas, C., et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* 434, 864–870.
- Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.V., Kolettas, E., Niforou, K., Zoumpouris, V.C., et al. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* 444, 633–637.
- Bartkova, J., Horejsi, Z., Sehested, M., Nesland, J.M., Rajpert-De Meyts, E., Skakkebaek, N.E., Stucki, M., Jackson, S., Lukas, J., and Bartek, J. (2007). DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. *Oncogene* 26, 7414–7422.
- Bindra, R.S., Gibson, S.L., Meng, A., Westermarck, U., Jasin, M., Pierce, A.J., Bristow, R.G., Classon, M.K., and Glazer, P.M. (2005). Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. *Cancer Res.* 65, 11597–11604.
- Branzei, D., and Foiani, M. (2007). Interplay of replication checkpoints and repair proteins at stalled replication forks. *DNA Repair (Amst.)* 6, 994–1003.
- Bristow, R.G., and Hill, R.P. (2008). Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. *Nat. Rev. Cancer* 8, 180–192.
- Coller, H.A., Grandori, C., Tamayo, P., Colbert, T., Lander, E.S., Eisenman, R.N., and Golub, T.R. (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. *Proc. Natl. Acad. Sci. USA* 97, 3260–3265.
- Corn, P.G., Ricci, M.S., Scata, K.A., Arsham, A.M., Simon, M.C., Dicker, D.T., and El-Deiry, W.S. (2005). Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. *Cancer Biol. Ther.* 4, 1285–1294.
- Covello, K.L., Kehler, J., Yu, H., Gordan, J.D., Arsham, A.M., Hu, C.J., Labosky, P.A., Simon, M.C., and Keith, B. (2006). HIF-2 α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. *Genes Dev.* 20, 557–570.
- Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre, M., Nuciforo, P.G., Bensimon, A., et al. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* 444, 638–642.
- Dimitrova, D.S., and Gilbert, D.M. (2000). Temporally coordinated assembly and disassembly of replication factories in the absence of DNA synthesis. *Nat. Cell Biol.* 2, 686–694.
- Ficenec, D., Osborne, M., Pradines, J., Richards, D., Felciano, R., Cho, R.J., Chen, R.O., Liefeld, T., Owen, J., Rutenberg, A., et al. (2003). Computational knowledge integration in biopharmaceutical research. *Brief. Bioinform.* 4, 260–278.
- Gordan, J.D., and Simon, M.C. (2007). Hypoxia-inducible factors: central regulators of the tumor phenotype. *Curr. Opin. Genet. Dev.* 17, 71–77.
- Gordan, J.D., Bertout, J.A., Hu, C.J., Diehl, J.A., and Simon, M.C. (2007a). HIF-2 α promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. *Cancer Cell* 11, 335–347.
- Gordan, J.D., Thompson, C.B., and Simon, M.C. (2007b). HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. *Cancer Cell* 12, 108–113.
- Gorgoulis, V.G., Vassiliou, L.V., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., Dittullo, R.A., Jr., Kastrinakis, N.G., Levy, B., et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* 434, 907–913.
- Halazonetis, T.D., Gorgoulis, V.G., and Bartek, J. (2008). An oncogene-induced DNA damage model for cancer development. *Science* 319, 1352–1355.
- Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P., and Krek, W. (2003). Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. *Nat. Cell Biol.* 5, 64–70.
- Herman, J.G., Latif, F., Weng, Y., Lerman, M.I., Zbar, B., Liu, S., Samid, D., Duan, D.S., Gnara, J.R., Linehan, W.M., et al. (1994). Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. *Proc. Natl. Acad. Sci. USA* 91, 9700–9704.
- Hook, S.S., Lin, J.J., and Dutta, A. (2007). Mechanisms to control rereplication and implications for cancer. *Curr. Opin. Cell Biol.* 19, 663–671.
- Hu, C.J., Wang, L.Y., Chodosh, L.A., Keith, B., and Simon, M.C. (2003). Differential roles of hypoxia-inducible factor 1 α (HIF-1 α) and HIF-2 α in hypoxic gene regulation. *Mol. Cell. Biol.* 23, 9361–9374.
- Huang, L.E., Bindra, R.S., Glazer, P.M., and Harris, A.L. (2007). Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression. *J. Mol. Med.* 85, 139–148.
- Kim, J.W., Tchernyshyov, I., Semenza, G.L., and Dang, C.V. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab.* 3, 177–185.
- Kim, W.Y., and Kaelin, W.G. (2004). Role of VHL gene mutation in human cancer. *J. Clin. Oncol.* 22, 4991–5004.
- Kondo, K., Kico, J., Nakamura, E., Lechpammer, M., and Kaelin, W.G., Jr. (2002a). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. *Cancer Cell* 1, 237–246.
- Kondo, K., Yao, M., Yoshida, M., Kishida, T., Shuin, T., Miura, T., Moriyama, M., Kobayashi, K., Sakai, N., Kaneko, S., et al. (2002b). Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. *Genes Chromosomes Cancer* 34, 58–68.

- Kondo, K., Kim, W.Y., Lechpammer, M., and Kaelin, W.G., Jr. (2003). Inhibition of HIF2 α is sufficient to suppress pVHL-defective tumor growth. *PLoS Biol.* 1, E83.
- Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M.J., Sauter, G., and Kallioniemi, O.P. (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat. Med.* 4, 844–847.
- Koshiji, M., Kageyama, Y., Pete, E.A., Horikawa, I., Barrett, J.C., and Huang, L.E. (2004). HIF-1 α induces cell cycle arrest by functionally counteracting Myc. *EMBO J.* 23, 1949–1956.
- Koshiji, M., To, K.K., Hammer, S., Kumamoto, K., Harris, A.L., Modrich, P., and Huang, L.E. (2005). HIF-1 α induces genetic instability by transcriptionally downregulating MutS α expression. *Mol. Cell* 17, 793–803.
- Lee, A.C., Fenster, B.E., Ito, H., Takeda, K., Bae, N.S., Hirai, T., Yu, Z.X., Ferrans, V.J., Howard, B.H., and Finkel, T. (1999). Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. *J. Biol. Chem.* 274, 7936–7940.
- Lee, S., Nakamura, E., Yang, H., Wei, W., Linggi, M.S., Sajan, M.P., Farese, R.V., Freeman, R.S., Carter, B.D., Kaelin, W.G., Jr., and Schlisio, S. (2005). Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. *Cancer Cell* 8, 155–167.
- Lonser, R.R., Glenn, G.M., Walther, M., Chew, E.Y., Libutti, S.K., Linehan, W.M., and Oldfield, E.H. (2003). von Hippel-Lindau disease. *Lancet* 361, 2059–2067.
- Lum, J.J., Bui, T., Gruber, M., Gordan, J.D., DeBerardinis, R.J., Covelto, K.L., Simon, M.C., and Thompson, C.B. (2007). The transcription factor HIF-1 α plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. *Genes Dev.* 21, 1037–1049.
- Mandriota, S.J., Turner, K.J., Davies, D.R., Murray, P.G., Morgan, N.V., Sowter, H.M., Wykoff, C.C., Maher, E.R., Harris, A.L., Ratcliffe, P.J., and Maxwell, P.H. (2002). HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. *Cancer Cell* 1, 459–468.
- Maranchie, J.K., Vasselli, J.R., Riss, J., Bonifacio, J.S., Linehan, W.M., and Klausner, R.D. (2002). The contribution of VHL substrate binding and HIF-1 α to the phenotype of VHL loss in renal cell carcinoma. *Cancer Cell* 1, 247–255.
- McCarthy, E.E., Celebi, J.T., Baer, R., and Ludwig, T. (2003). Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. *Mol. Cell Biol.* 23, 5056–5063.
- Milbrandt, J.D., Heintz, N.H., White, W.C., Rothman, S.M., and Hamlin, J.L. (1981). Methotrexate-resistant Chinese hamster ovary cells have amplified a 135-kilobase-pair region that includes the dihydrofolate reductase gene. *Proc. Natl. Acad. Sci. USA* 78, 6043–6047.
- Motzer, R.J., and Bukowski, R.M. (2006). Targeted therapy for metastatic renal cell carcinoma. *J. Clin. Oncol.* 24, 5601–5608.
- Nishitani, H., Sugimoto, N., Roukos, V., Nakanishi, Y., Saijo, M., Obuse, C., Tsurimoto, T., Nakayama, K.I., Nakayama, K., Fujita, M., et al. (2006). Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. *EMBO J.* 25, 1126–1136.
- Nuciforo, P.G., Luise, C., Capra, M., Pelosi, G., and d'Adda di Fagnaga, F. (2007). Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. *Carcinogenesis* 28, 2082–2088.
- O'Connell, B.C., Cheung, A.F., Simkevich, C.P., Tam, W., Ren, X., Mateyak, M.K., and Sedivy, J.M. (2003). A large scale genetic analysis of c-Myc-regulated gene expression patterns. *J. Biol. Chem.* 278, 12563–12573.
- Papandreou, I., Cairns, R.A., Fontana, L., Lim, A.L., and Denko, N.C. (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab.* 3, 187–197.
- Pugh, C.W., and Ratcliffe, P.J. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. *Nat. Med.* 9, 677–684.
- Rathmell, W.K., Hickey, M.M., Bezman, N.A., Chmielecki, C.A., Carraway, N.C., and Simon, M.C. (2004). In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. *Cancer Res.* 64, 8595–8603.
- Raval, R.R., Lau, K.W., Tran, M.G., Sowter, H.M., Mandriota, S.J., Li, J.L., Pugh, C.W., Maxwell, P.H., Harris, A.L., and Ratcliffe, P.J. (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. *Mol. Cell Biol.* 25, 5675–5686.
- Ray, S., Atkuri, K.R., Deb-Basu, D., Adler, A.S., Chang, H.Y., Herzenberg, L.A., and Felsher, D.W. (2006). MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. *Cancer Res.* 66, 6598–6605.
- Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., and Mesirov, J.P. (2006). GenePattern 2.0. *Nat. Genet.* 38, 500–501.
- Stolle, C., Glenn, G., Zbar, B., Humphrey, J.S., Choyke, P., Walther, M., Pack, S., Hurley, K., Andrey, C., Klausner, R., and Linehan, W.M. (1998). Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Hum. Mutat.* 12, 417–423.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* 102, 15545–15550.
- Turner, K.J., Moore, J.W., Jones, A., Taylor, C.F., Cuthbert-Heavens, D., Han, C., Leek, R.D., Gatter, K.C., Maxwell, P.H., Ratcliffe, P.J., et al. (2002). Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. *Cancer Res.* 62, 2957–2961.
- Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T.K., Hampton, G.M., and Wahl, G.M. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. *Mol. Cell* 9, 1031–1044.
- Wang, V., Davis, D.A., Haque, M., Huang, L.E., and Yarchoan, R. (2005). Differential gene up-regulation by hypoxia-inducible factor-1 α and hypoxia-inducible factor-2 α in HEK293T cells. *Cancer Res.* 65, 3299–3306.
- Wang, W. (2007). Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. *Nat. Rev. Genet.* 8, 735–748.
- Xu, X., Weaver, Z., Linke, S.P., Li, C., Gotay, J., Wang, X.W., Harris, C.C., Ried, T., and Deng, C.X. (1999). Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. *Mol. Cell* 3, 389–395.
- Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K.I., Dang, C.V., and Semenza, G.L. (2007). HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. *Cancer Cell* 11, 407–420.